2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MPN, CML, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

5486 KIT mutant mast cells drive monocytic skewing in systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)

Nana Adjoa Dankyi, MBChB, PhD, Christopher Ryder, MD PhD2, Surendra Neupane, PhD3, Amara Pang, BS4, Hannah Newman5, Anthony Michael Hunter, MD6, Maria Balasis7, Traci Kruer, PhD8, Amy McLemore, MS9, Zena Komrokji10, Rami Komrokji, MD11, Najla Al Ali, MS12, Sakshi Buchke13, Somedeb Ball, MD14, Michael R. Savona, MD15, David Sallman, MD16, Andrew T Kuykendall, MD17, Tracy George, MD18, Tsewang Tashi, MD19, Theodore Paul Braun, MD PhD20, Julia Maxson, PhD21, Eric Padron, MD22
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Knight Cancer Institute, Portland, Oregon, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Vanderbilt University School of Medicine, Nashville, Tennessee, United States
15 Vanderbilt University School of Medicine, Nashville, Tennessee, United States
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 University of Utah Huntsman Cancer Institute, Salt lake City, Utah, United States
19 University of Utah Huntsman Cancer Institute, Salt lake City, Utah, United States
20 Oregon Science and Health University, Portland, Oregon, United States
21 Oregon Science and Health University, Portland, Oregon, United States
22 Moffitt Cancer Center, Tampa, Florida, United States

Systemic Mastocytosis (SM) is characterized by clonal expansion of abnormal KIT mutant (KITMT) mast cells. SM-AHN is the commonest advanced SM and chronic myelomonocytic leukemia (CMML), a malignancy hallmarked by peripheral blood monocytosis, is the most frequent AHN observed. However, the underlying biology responsible for this association is unknown. We hypothesize that this association is driven by KITMT mast cells that lead to monocytic skewing and reasoned that if driven by the presence of KITMT cells, other non-CMML AHNs could have monocytic skewing without meeting diagnostic criteria for CMML. We thus developed multi-institutional retrospective cohorts and compared SM-AHN/KITMT AHNs to their corresponding AHN without SM or KITMT. Using an absolute monocyte count (AMC) cutoff of 0.5k/uL, we observed more frequent monocytic skewing in SM-MDS (54.5% n=11 vs 25.3% n=4653, p=0.02), SM-AML/KITMT AML (60% n= 70 vs 39.3% n= 835, p=0.0009) and SM-MF/KITMT MF (77.9% n=9 vs 42.4% n=389, p=0.04). To determine whether KIT mutation was sufficient to cause monocytosis in murine models, we probed a novel murine model of inducible Kit D814V/WT mutation in hematopoietic stem and progenitor cells (abs26-3451). In addition to recapitulating features of advanced SM, we observed higher peripheral blood AMC and an increase in Ly6C+ monocytes relative to controls (p<0.001).

Next, we developed a heterotopic murine model using subcutaneous AHN cell lines (THP-1, U937, or HL-60) in NSG mice with or without concomitant HMC1.2 mast cell flank injections. Interestingly, we observed an increase in AHN tumor size in HMC1.2-containing mice compared to control in short term measurement (days 10-17) and a subsequent decrease in measurements (days 21-28) phenocopying what may be expected in differentiating tumors. (fold change [FC]: THP-1=0.56 p=0.049, n=8/group; U937=0.54 p=0.02, n=7/group; HL-60=0.62 p=0.006, n=8/group). This growth pattern was recapitulated in patient derived xenografts (PDX) of primary CMML bone marrow with or without subcutaneous HMC1.2 cells where we observed that mice with concomitant HMC1.2 tumors had lower human CD45 engraftment than mice without in bone marrow (65.37% vs 84.29% p=0.03) and spleen (29.87% vs 47.96% p=0.04, n=4/group). Interestingly, an associated shift of classical monocyte frequency (85% vs 91% p=0.04) toward non-classical monocytes (11% vs 6.6% p=0.03) was observed suggesting increased terminal monocytic differentiation. Consistent with this, HMC1.2 supernatant-grown AHN cell lines demonstrated a shift from expansion of classical monocytes at early time points to expansion of non-classical monocytes at later time points supporting a similar differentiation effect.  

To uncover potential factors driving this phenotype we performed transcription factor analysis from bulk RNA-seq of heterotopic tumors as well as plasma and cell culture supernatant cytokine analysis. These revealed enrichment of multiple cytokines associated with myeloid differentiation in mice with concomitant HMC1.2 tumors at the transcriptional and protein levels. Given the established role of TNF-alpha in differentiation of non-classical monocytes and its consistent increase in HMC1.2-exposed plasma and transcriptome across all in vitro and in vivo models, we explored whether exogenous TNF-alpha could phenocopy KITMT mast cell exposure in vitro. Indeed, all AHN cell lines treated with TNF-alpha showed decreased proliferation as well as an increase in differentiation markers consistent with our SM-AHN models.

Finally, we tested whether avapritinib, a potent mutant KIT inhibitor, would result in loss of monocytic differentiation and terminal arrest in our SM-AHN models. Indeed, we observed a reduction in phenotypes of monocyte differentiation in avapritinib-treated mice. Moreover, increased TNF-alpha secretion observed in vehicle bilateral mice was attenuated with treatment.

Collectively, we demonstrate that KIT mutations are associated with monocyte skewing across many human AHNs and in a novel murine model of advanced SM. Moreover, we demonstrate that KIT mutant mast cells are sufficient to induce monocyte skewing and terminal differentiation in PDXs, heterotopic murine models and in vitro systems. Last, we nominate TNF-alpha as a possible effector of this phenomenon as it was sufficient to recapitulate features of monocyte skewing observed in SM-AHN models. These data provide a novel biologic framework to explain monocytosis in SM-AHN.

Nana Adjoa Dankyi, MBChB, PhD: No relevant conflicts of interest to declare.